# A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.

> **NCT00282464** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 392 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** Geodon (Ziprasidone)

## Key facts

- **NCT ID:** NCT00282464
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 392 (ACTUAL)
- **Last updated:** 2021-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00282464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00282464, "A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00282464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*